MWNA
ANIP icon

Marshall Wace North America’s ANI Pharmaceuticals ANIP Stock Holding History

Marshall Wace North America’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,355
Closed -$428K – 1369
2018
Q1 		$428K Sell
7,355
-39,530
-84% -$2.51M ﹤0.01% 1188
2017
Q4 		$3.02M Buy
+46,885
New +$2.92M 0.02% 720

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Marshall Wace North America's ANIP Position: Q2 2018 in Review

Marshall Wace North America sold out of ANI Pharmaceuticals (ANIP) in Q2 2018, closing a stake of 7,355 shares — an estimated $428K sold.

Marshall Wace North America first reported a position in ANIP in Q4 2017 and held it in 2 quarters. The position peaked at $3.02M in Q4 2017. 184 funds tracked by Wall St. Rank hold ANIP as of Q2 2018.

  • Marshall Wace North America reported no remaining ANI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Marshall Wace North America sold 7,355 ANI Pharmaceuticals shares in Q2 2018, an estimated $428K.
  • Marshall Wace North America first reported a position in ANI Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Marshall Wace North America's ANI Pharmaceuticals position peaked at $3.02M in Q4 2017.
  • 184 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2018.

Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.